Pathology: Type 1 Diabetes

• Publication date: June 2010

GlobalData, the market analysis specialist, has released a new report, “”. The report is an essential source of information and analysis on the global type 1 diabetes industry . The report identifies the major industry developments shaping and driving the global type 1 diabetes industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry posi...

GlobalData, the market analysis specialist, has released a new report, “”. The report is an essential source of information and analysis on the global type 1 diabetes industry . The report identifies the major industry developments shaping and driving the global type 1 diabetes industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the existing industry leaders. Most importantly, the report provides valuable insights on the new product development within the global type 1 diabetes segment . GlobalData estimates the global type 1 diabetes therapeutics industry to have been valued at USD 2.7 billion in 2009. It is projection to grow at 6.1% annually for the next seven years to reach USD 4.4 billion by 2017. This growth is primarily attributed to the increase in the average cost of therapy for type 1 diabetes and increases in the diseased and treatment seeking populations. The available treatment options are moderately successful in meeting the industry demand leading to a moderate level of unmet need. A significant industry potential exists to be exploited by any new entrant that will cater to the unmet needs for more convenient products with better efficacy and safety. GlobalData finds that the emerging therapies in the pipeline are expected to capture a small portion of the unmet need. The pipeline for type 1 diabetes appears to be moderately strong. Despite the high proportion of first-in-class drugs in the pipeline, the pipeline is not very strong as the development stage products are not likely to cater to the needs of all type 1 diabetes patients. While the new product development are not strong enough to impact the current industry considerably, the success of these products will drive the industry in the long run.

Scope of the Research

The scope of the report includes:
- Annualized global type 1 diabetes industry revenues data from data from 2001 to 2009, projection for eight years to 2017.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future industry competition in the global type 1 diabetes industry .
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and implications for future industry associated with type 1 diabetes.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of new product development and technologies and by identifying industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes industry .
- Drive revenues by understanding major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global type 1 diabetes industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global type 1 diabetes industry landscape? – Identify, understand and decide.

Global Pathology Industry

1 Table of contents 3
I. 1 List of Data tables 5
I. 2 List of Charts 5

II Type 1 Diabetes Therapeutics March ket: March ket Characterization 6
II. 1 Overview 6
II. 2 Type 1 Diabetes March ket Size 6
II. 3 Type 1 Diabetes Therapeutics March ket Forecasted data and CAGR 7
II. 4 Drivers and Barriers for the Type 1 Diabetes Therapeutics March ket 8
II. 4.1 Drivers for the Type 1 Diabetes Therapeutics March ket 8
II. 4.2 Restraints for the Type 1 Diabetes Therapeutics March ket 9
II. 5 Opportunity and Unmet Need 10
II. 6 Key Takeaway 11

III Type 1 Diabetes Therapeutics March ket: Competitive Assessment 12
III. 1 Overview 12
III. 2 Strategic Competitor Assessment 12
III. 3 Product Profile for the Major March keted Products in the Type 1 Diabetes Disease March ket 13
III. 3.1 Lantus (Insulin Glargine) 13
III. 3.2 Humulin (Human Insulin) 16
III. 3.3 Humalog (Insulin Lispro) 17
III. 3.4 November olog (Insulin Aspart) 19
III. 3.5 November olin (Human Insulin) 20
III. 3.6 Apidra (Insulin Glulisine) 21
III. 3.7 Levemir (Insulin Detemir) 23
III. 4 Key Takeaway 25

IV Type 1 Diabetes Therapeutics March ket: Pipeline Assessment 26
IV. 1 Overview 26
IV. 2 Strategic Pipeline Assessment 26
IV. 2.1 Technology Trends Analytic Framework 26
IV. 3 Type 1 Diabetes Therapeutics – Promising Drugs under Clinical Development 27
IV. 4 Molecule Profile for Promising Drugs under Clinical Development 28
IV. 4.1 rhGAD65 (Diamyd) 28
IV. 4.2 DiaPep277 28
IV. 4.3 Otelixizumab 29
IV. 4.4 Oral-lyn 30
IV. 5 Type 1 Diabetes Therapeutics March ket – Clinical Pipeline by Mechanism of Action 31
IV. 6 Type 1 Diabetes Pipeline – Pipeline by Clinical Phases of Development 32
IV. 6.1 Type 1 Diabetes Therapeutics – Filed and Approved Drugs 32
IV. 6.2 Type 1 Diabetes Therapeutics – Phase III Clinical Pipeline 33
IV. 6.3 Type 1 Diabetes Therapeutics – Phase II Clinical Pipeline 33
IV. 6.4 Type 1 Diabetes Therapeutics – Phase I Clinical Pipeline 35
IV. 6.5 Type 1 Diabetes Therapeutics – Preclinical-Discovery Pipeline 35
IV. 7 Key Takeaway 36

V Type 1 Diabetes March ket: Implications for Future March ket Competition 37

VI Type Diabetes Therapeutics March ket: Future Players in the Type 1 Diabetes Therapeutics March ket 39
VI. 1 Introduction 39
VI. 2 November o Nordisk 39
VI. 2.1 Business Overview 39
VI. 2.2 Metabolic Disorders Portfolio 40
VI. 2.3 Type 1 Diabetes Pipeline Portfolio 41
VI. 3 GlaxoSmithKline 42
VI. 3.1 Business Overview 42
VI. 3.2 Metabolic Disorders Portfolio 43
VI. 3.3 Type 1 Diabetes Pipeline Portfolio 43
VI. 4 Eli Lilly 44
VI. 4.1 Business Overview 44
VI. 4.2 Metabolic Disorders Portfolio 45
VI. 4.3 Type 1 Diabetes Pipeline Portfolio 45
VI. 5 Sanofi-Aventis 46
VI. 5.1 Business Overview 46
VI. 5.2 Metabolic Disorders Portfolio 47
VI. 5.3 Type 1 Diabetes Pipeline Portfolio 47

VII Type 1 Diabetes Therapeutics March ket: Appendix 48
VII. 1 Definitions 48
VII. 2 Scope of Pipeline Research 48
VII. 3 Abbreviations 48
VII. 4 Research Methodology 49
VII. 4.1 Coverage 50
VII. 4.2 Secondary Research 50
VII. 4.3 Forecasted data ing 50
VII. 4.4 Primary Research 52
VII. 4.5 Expert Panel Validation 53
VII. 5 Contact Us 53
VII. 6 Disclaimer 53
VII. 7 Sources 54

1.1 List of Data tables
Data table 1: Type 1 Diabetes Therapeutics March ket, Global, Sales s ($bn), from 2001 to 2009 7
Data table 2: Type 1 Diabetes Therapeutics March ket, Global, Sales Forecasted data s ($bn), from 2009 to 2017 8
Data table 3: Type 1 Diabetes Therapeutics March ket, Lantus, Clinical Studies Outcome for Efficacy, 2010 14
Data table 4: Type 1 Diabetes Therapeutics March ket, Lantus, Adverse Events in 28-Week Clinical Trials of Adults and Children With Type 1 Diabetes, 2010 14
Data table 5: Type 1 Diabetes Therapeutics March ket, Lantus, Clinical Studies Outcome for Safety, 2010 15
Data table 6: Humulin - Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies for Type 1 Diabetes, 2010 16
Data table 7: Humulin – Results of Three Month Cross-Over Studies Comparing Humulin with Humalog in Type 1 Diabetes, 2010 17
Data table 8: Type 1 Diabetes Therapeutics March ket, Humalog, Glycemic Parameters at the End of Treatment Period in Randomized Patients in Three Months Cross-Over Studies, 2010 18
Data table 9: Humalog – Results of a Two Month Study Comparing the Use of Humalog and Humulin With Sulfonyluria (SU) Therapy, 2010 19
Data table 10: Type 1 Diabetes Therapeutics March ket, November olog, Glycemic Parameters at the End of 24 Week Study, 2010 20
Data table 11: Apidra – Efficacy Result of 26-Week Study Comparing Apidra with Insulin Lispro, 2010 22
Data table 12: Apidra – Efficacy Result of 26-Week Study Comparing Apidra with Regular Insulin 22
Data table 13: Apidra – Adverse Reactions Observed in Pooled Studies in Type 1 Diabetic Adults, 2010 22
Data table 14: Levemir – Efficacy Result in 16-Week Non Blinded Study, 2010 23
Data table 15: Major March keted Products Comparison in the Type 1 Diabetes Therapeutics March ket, 2010 24
Data table 16: Type 1 Diabetes Therapeutics – Most Promising Drugs Under Clinical Development, 2010 27
Data table 17: Type 1 Diabetes Therapeutics – Filed and Approved Drugs, 2010 32
Data table 18: Type 1 Diabetes Therapeutics – Phase III Clinical Pipeline, 2010 33
Data table 19: Type 1 Diabetes Therapeutics – Phase II Clinical Pipeline, 2010 33
Data table 20: Type 1 Diabetes Therapeutics – Phase I Clinical Pipeline, 2010 35
Data table 21: Type 1 Diabetes Therapeutics – Preclinical-Discovery Pipeline, 2010 35
Data table 22: Genzyme – Metabolic Disorders March keted Products, 2010 40
Data table 23: November o Nordisk - Metabolic Disorders Pipeline Products, 2010 41
Data table 24: GlaxoSmithKline – Metabolic Disorders March keted Products, 2010 43
Data table 25: GlaxoSmithKline - Metabolic Disorders Pipeline Products, 2010 43
Data table 26: Eli Lilly – Metabolic Disorders March keted Products, 2010 45
Data table 27: Eli Lilly – Metabolic Disorders Pipeline Products, 2010 45
Data table 28: Sanofi-Aventis – Metabolic Disorders March keted Products, 2010 47
Data table 29: Sanofi-Aventis – Metabolic Disorders Pipeline Products, 2010 47

1.2 List of Charts
Chart 1: Type 1 Diabetes Therapeutics March ket, Global, Sales s ($bn), from 2001 to 2009 7
Chart 2: Type 1 Diabetes Therapeutics March ket, Global, Sales Forecasted data s ($bn), from 2009 to 2017 8
Chart 3: Opportunity and Unmet Need in the Type 1 Diabetes Therapeutics March ket, 2010 10
Chart 4: Strategic Competitor Assessment of the Major March keted Products in Type 1 Diabetes Therapeutics, 2010 13
Chart 5: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics Pipeline, 2010 26
Chart 6: Technology Trends Analytic Framework of the Type 1 Diabetes Therapeutics
Pipeline – Description, 2010 27
Chart 7: Type 1 Diabetes Therapeutics March ket – Clinical Pipeline by Mechanism of Action, 2010 31
Chart 8: Type 1 Diabetes Therapeutics Pipeline by Phase of Clinical Development, 2010 32
Chart 9: Implications for Future March ket Competition in the Type 1 Diabetes March ket, 2010 37
Chart 10: Type 1 Diabetes Therapeutics March ket – Clinical Pipeline by Firms, 2010 39
Chart 11: GlobalData Methodology, 2010 49
Chart 12: GlobalData March ket Forecasted data ing Model, 2010 52

Companies mentioned
November o Nordisk
GlaxoSmithKline
Eli Lilly
Sanofi-Aventis